Covered recipient · General Payments record
MISAKO NAGASAKA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$119,923.27
109 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,615.00 | 19 |
| Consulting Fee | $41,011.33 | 26 |
| Travel and Lodging | $10,281.53 | 31 |
| Food and Beverage | $2,915.42 | 32 |
| Education | $99.99 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $52,399.52 | 52 |
| PFIZER INC. | $26,517.61 | 12 |
| Regeneron Healthcare Solutions, Inc. | $22,296.15 | 17 |
| AstraZeneca Pharmaceuticals LP | $6,290.22 | 4 |
| E.R. Squibb & Sons, L.L.C. | $4,255.48 | 12 |
| Eli Lilly and Company | $3,316.12 | 3 |
| Regeneron Pharmaceuticals, Inc. | $2,163.00 | 2 |
| Janssen Global Services, LLC | $1,559.75 | 2 |
| Boehringer Ingelheim International GmbH | $833.33 | 1 |
| Daiichi Sankyo Inc. | $178.33 | 3 |
| Genentech USA, Inc. | $113.76 | 1 |
Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MISAKO NAGASAKA
NPI 1063707958 · CMS profile ID 1390221
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ORANGE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MISAKO NAGASAKA, NPI 1063707958, CMS profile ID 1390221, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063707958?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
109 matching records · $119,923.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–109 of 109.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Global Services, LLC | $159.75 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077590519 | CMS |
| Regeneron Healthcare Solutions, Inc. | $52.08 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114121501 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.04 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114121503 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,740.00 | 02/02/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104584826 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,300.00 | 01/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101286604 | CMS |
| Janssen Biotech, Inc. | $100.81 | 01/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078315380 | CMS |
| Janssen Biotech, Inc. | $241.25 | 01/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078315788 | CMS |
| Boehringer Ingelheim International GmbH | $833.33 | 01/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117858957 | CMS |
| AstraZeneca Pharmaceuticals LP | $685.00 | 01/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104482992 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,929,743.35 | 84 |
| PY2024 | Recipient | $19,703.32 | 2 |
| PY2024 | Principal investigator | $1,058,712.92 | 69 |
| PY2023 | Principal investigator | $703,392.40 | 48 |
| PY2022 | Principal investigator | $359,817.00 | 16 |
| PY2021 | Recipient | $749.32 | 1 |
| PY2021 | Principal investigator | $768,456.39 | 104 |
| PY2020 | Recipient | $747.74 | 2 |
| PY2020 | Principal investigator | $1,300,906.82 | 400 |
| PY2019 | Principal investigator | $793,187.83 | 178 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
84 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $10,428.00 | 12/25/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure | No dispute reported | 06/30/2026 | 1175441675 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $69,164.21 | 12/23/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220796465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11,880.00 | 12/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223352388 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42,886.05 | 12/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223352390 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $13,877.00 | 12/16/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190336007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,759.02 | 12/15/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441776 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,403.52 | 12/12/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175441557 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577508 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $71.84 | 12/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577510 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 12/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577512 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $61,395.64 | 11/30/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995236 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $184,186.92 | 11/30/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995238 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $263.70 | 11/19/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995240 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $174.90 | 11/19/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995242 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.94 | 11/19/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995244 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $15,828.00 | 11/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190336003 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $16,190.00 | 11/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190336011 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,982.72 | 11/11/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220796463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,236.00 | 11/10/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175441787 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,476.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure | No dispute reported | 06/30/2026 | 1175441904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $18,222.12 | 11/06/2025 | Covered Recipient Teaching Hospital Uci Medical Center | U31402-A-U201 | No dispute reported | 06/30/2026 | 1223352386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,936.00 | 11/06/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175441814 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577506 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,616.92 | 10/23/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441388 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,403.52 | 10/23/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175441400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,442.32 | 10/23/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441579 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577502 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,952.00 | 09/29/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441875 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,505.13 | 09/22/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,990.00 | 09/18/2025 | Covered Recipient Teaching Hospital FOUNTAIN VALLEY REG MEDICAL CENTER | A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184127248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,105.76 | 09/18/2025 | Covered Recipient Teaching Hospital FOUNTAIN VALLEY REG MEDICAL CENTER | A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184127250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,620.00 | 09/18/2025 | Covered Recipient Teaching Hospital FOUNTAIN VALLEY REG MEDICAL CENTER | A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184127252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,670.92 | 09/18/2025 | Covered Recipient Teaching Hospital FOUNTAIN VALLEY REG MEDICAL CENTER | A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184127254 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,795.00 | 09/18/2025 | Covered Recipient Teaching Hospital FOUNTAIN VALLEY REG MEDICAL CENTER | A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184127256 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,476.00 | 08/29/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441899 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $36,617.00 | 08/26/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190328363 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $29,977.00 | 08/26/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190328365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,505.13 | 08/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441798 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,403.52 | 08/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175441917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,952.00 | 08/11/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441435 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577498 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $21,256.00 | 07/30/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,490.09 | 07/24/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441942 |
| Principal investigator 1 | Blueprint Medicines Corporation | $15,732.00 | 07/04/2025 | Covered Recipient Teaching Hospital Uci Medical Center | BLU-945-1101 | No dispute reported | 06/30/2026 | 1235784397 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,476.00 | 06/26/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441532 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81.62 | 06/24/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995232 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $26.60 | 06/24/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995234 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,505.13 | 06/23/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,403.52 | 06/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175441304 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,697.35 | 06/16/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,904.00 | 06/09/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441887 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $14,645.00 | 06/03/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. | No dispute reported | 06/30/2026 | 1235999998 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,297.00 | 06/02/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175441857 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,490.09 | 05/22/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,858.00 | 05/12/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441793 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $98,592.91 | 05/07/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2 positive) (DESTINY-Lung03). | No dispute reported | 06/30/2026 | 1185540685 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34,432.95 | 04/25/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441893 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,442.32 | 04/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441770 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,640.00 | 04/17/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190326402 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $12,480.00 | 04/17/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190338918 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32,972.96 | 04/11/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220796461 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577490 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,476.00 | 03/31/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441430 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,395.36 | 03/26/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase III Double-blind Randomised Placebo-Controlled International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer following Complete Tumour Resection | No dispute reported | 06/30/2026 | 1185540687 |
| Principal investigator 1 | Amgen Inc. | $28,285.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201) | No dispute reported | 06/30/2026 | 1246638566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,331.74 | 03/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441538 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $16,671.55 | 03/12/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516761 |
| Principal investigator 1 | Eli Lilly and Company | $3,947.80 | 03/07/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) | No dispute reported | 06/30/2026 | 1187871717 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $168,444.93 | 03/03/2025 | Non-covered Recipient Entity Uci Health Fountain Valley | A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 | No dispute reported | 06/30/2026 | 1236530471 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,476.00 | 02/28/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441610 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,600.67 | 02/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441573 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $13,958.00 | 02/05/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516771 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,428.00 | 02/03/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After O | No dispute reported | 06/30/2026 | 1175441910 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577484 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $135,027.90 | 01/29/2025 | Covered Recipient Teaching Hospital Uci Medical Center | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) | No dispute reported | 06/30/2026 | 1185540689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $65,856.46 | 01/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175441973 |
| Principal investigator 1 | Eli Lilly and Company | $236,406.60 | 01/02/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1187877439 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Non-covered Recipient Entity University Of California Irvine | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577488 |